List view / Grid view
Genflow have announced a scientific research collaboration with the University of Rochester’s Aging Research Center. Together, they will study the ageing process in liver tissue.
Researchers have developed a new method to screen drugs for Alzheimer’s disease, shedding light on why current drugs have failed and identifying novel drug targets.
Pre-clinical research has found that CAR T cells can suppress gastrointestinal cancer cells without causing harm to healthy tissues.
Researchers have created an implantable biotechnology that produces and releases CAR T cells for attacking cancerous tumours.
Research in mice has shown that adding anti-inflammatory medication to immunotherapy and standard chemotherapy drugs may provide long-term suppression of aggressive bladder tumour growth.
NanoTemper Technologies has announced the launch of Spectral Shift technology with its Dianthus instrument.
Sino Biological, Inc. has announced a new contract research services partnership with Ainnocence, Inc.
A new study from Niigata University has found a binding protein that is vital for proper development of the central nervous system.
Scientists have created what they believe is the first rat model of Down’s syndrome. The animal model shares features with human Down’s syndrome, which will allow for efficient testing of new therapies.
Novel research has shown that morphological fingerprinting could help identify side effects of new bioactive compounds in drug discovery.
Scientists have discovered a new strategy that can make pancreatic tumours visible to the immune systems of mice and vulnerable to immune attack.
Scientists have created a pipeline for identifying, prioritising and evaluating potential tumour antigens for personalised cancer vaccines.
Scientists have discovered the essential role of a ligand-dependent corepressor to potentially enable cancer cells to present tumour antigens on their surfaces.
New research has discovered metabolic mechanisms that contribute to how ovarian cancer escapes from immune attack and how combination therapies can exploit these pathways to improve ovarian cancer treatment.
A new study has highlighted an enzyme called ART1 as a promising target for immunity-boosting cancer treatments.
